These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7948312)

  • 1. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.
    Link H; Maschmeyer G; Meyer P; Hiddemann W; Stille W; Helmerking M; Adam D
    Ann Hematol; 1994 Nov; 69(5):231-43. PubMed ID: 7948312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society].
    Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
    Med Klin (Munich); 1994 Mar; 89(3):114-23. PubMed ID: 8196571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II.
    Schiel X; Link H; Maschmeyer G; Glass B; Cornely OA; Buchheidt D; Wilhelm M; Silling G; Helmerking M; Hiddemann W; Ostermann H; Hentrich M
    Infection; 2006 Jun; 34(3):118-26. PubMed ID: 16804654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1,260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Ehrlich Society for Chemotherapy.
    Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Adam D
    Onkologie; 1990 Feb; 13(1):38-42. PubMed ID: 2186323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study.
    Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
    Cancer; 1994 May; 73(9):2296-304. PubMed ID: 8168033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.
    Jeddi R; Achour M; Amor RB; Aissaoui L; Bouterâa W; Kacem K; Lakhal RB; Abid HB; BelHadjAli Z; Turki A; Meddeb B
    Hematology; 2010 Feb; 15(1):28-32. PubMed ID: 20132659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
    Link H; Böhme A; Cornely OA; Höffken K; Kellner O; Kern WV; Mahlberg R; Maschmeyer G; Nowrousian MR; Ostermann H; Ruhnke M; Sezer O; Schiel X; Wilhelm M; Auner HW; ;
    Ann Hematol; 2003 Oct; 82 Suppl 2():S105-17. PubMed ID: 13680173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H
    Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial agents in neutropenic patients with unexplained fever.
    Shevchuk YM
    J Infect Dis; 1991 Jan; 163(1):203. PubMed ID: 1984471
    [No Abstract]   [Full Text] [Related]  

  • 12. Infections of febrile neutropenic patients in malignant hematological diseases.
    Rókusz L; Liptay L
    Mil Med; 2003 May; 168(5):355-9. PubMed ID: 12775168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventional antimicrobial therapy in febrile neutropenic patients.
    Maschmeyer G
    Diagn Microbiol Infect Dis; 1999 Jul; 34(3):205-12. PubMed ID: 10403100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
    Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
    Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
    Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
    Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.